|
1
|
Mayo SC and Pawlik TM: Current management
of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol.
3:131–144. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai
SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial
of cetuximab plus chemotherapy for patients with KRAS wild- type
unresectable colorectal liver-limited metastases. J Clin Oncol.
31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris EJ, Forman D, Thomas JD, Quirke P,
Taylor EF, Fairley L, Cottier B and Poston G: Surgical management
and outcomes of colorectal cancer liver metastases. Br J Surg.
97:1110–1118. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Folprecht G, Gruenberger T, Bechstein W,
Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J,
Lang H, Trarbach T, et al: Survival of patients with initially
unresectable colorectal liver metastases treated with
FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary
concept (CELIM study). Ann Oncol. 25:1018–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Formica V and Roselli M: Targeted therapy
in first line treatment of RAS wild type colorectal cancer. World J
Gastroenterol. 21:2871–2874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi L, Wu C, Wu J, Zhou W, Ji M, Zhang H,
Zhao J, Huang Y, Pei H, Li Z, et al: Computed tomography-guided
permanent brachytherapy for locoregional recurrent gastric cancer.
Radiat Oncol. 7:1142012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi L, Li X, Pei H, Zhao J, Qiang W, Wang
J, Xu B, Chen L, Wu J, Ji M, et al: Phase II study of computed
tomography-guided (125)I-seed implantation plus chemotherapy for
locally recurrent rectal cancer. Radiother Oncol. 118:375–381.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X,
Sun M, Wen W, Dai X, Yang M, et al: PD-1 blockade boosts
radiofrequency ablation-elicited adaptive immune responses against
tumor. Clin Cancer Res. 22:1173–1184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi L, Zhao J, Lu Q, Chen X, Wang H, Jiang
Y, Wu J, Ji M, Xu B, Chen L, et al: Initial hepatic artery infusion
and systemic chemotherapy for asymptomatic colorectal cancer with
un-resectable liver metastasis. Int J Clin Exp Med. 8:1000–1008.
2015.PubMed/NCBI
|
|
12
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun M: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Skitzki JJ and Chang AE: Hepatic artery
chemotherapy for colorectal liver metastases: Technical
considerations and review of clinical trials. Surg Oncol.
11:123–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eng OS, Tsang AT, Moore D, Chen C,
Narayanan S, Gannon CJ, August DA, Carpizo DR and Melstrom LG:
Outcomes of microwave ablation for colorectal cancer liver
metastases: A single center experience. J Surg Oncol. 111:410–413.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Lu J, Liu L, Liu T, Chen K, Liu F
and Huang G: Clinical application of CT-guided (125)I seed
interstitial implantation for local recurrent rectal carcinoma.
Radiat Oncol. 6:1382011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Loon K and Venook AP: Curable patient
with metastatic colorectal cancer: Balancing effective therapies
and toxicities. J Clin Oncol. 32:991–996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Venderbosch S, de Wilt JH, Teerenstra S,
Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME,
Mol L, Punt CJ and Koopman M: Prognostic value of resection of
primary tumor in patients with stage IV colorectal cancer:
Retrospective analysis of two randomized studies and a review of
the literature. Ann Surg Oncol. 18:3252–3260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tournigand C, Samson B, Scheithauer W,
Lledo G, Viret F, Andre T, Ramée JF, Tubiana-Mathieu N, Dauba J,
Dupuis O, et al: Bevacizumab (Bev) with or without erlotinib as
maintenance therapy, following induction first-line chemotherapy
plus Bev, in patients with metastatic colorectal cancer (mCRC):
Efficacy and safety results of the international GERCOR DREAM phase
III trial. J Clin Oncol. 30(suppl): S35002012. View Article : Google Scholar
|
|
19
|
Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin
N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, et
al: Bevacizumab+ capecitabine as maintenance therapy after initial
bevacizumab+ XELOX treatment in previously untreated patients with
metastatic colorectal cancer: Phase III ‘stop and go’ study
results-a Turkish oncology group trial. Oncology. 85:328–335. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Petre EN, Jia X, Thornton RH, Sofocleous
CT, Alago W, Kemeny NE and Solomon SB: Treatment of pulmonary
colorectal metastases by radiofrequency ablation. Clin Colorectal
Cancer. 12:37–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou P, Liang P, Dong B, Yu X, Han Z and
Xu Y: Phase I clinical study of combination therapy with microwave
ablation and cellular immunotherapy in hepatocellular carcinoma.
Cancer Biol Ther. 11:450–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Yuan H and Liu J: The effects of
CT guided interstitial 125I seed implantation in the treatment of
recurrent colorectal cancer. J Chin Radiation Oncol. 15:319–322.
2006.
|
|
23
|
Tournigand C, Cervantes A, Figer A, Lledo
G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, et
al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with
oxaliplatin in a stop-and-Go fashion in advanced colorectal
cancer-a GERCOR study. J Clin Oncol. 24:394–400. 2006. View Article : Google Scholar : PubMed/NCBI
|
